News & Events

  • 05 May 2017
  • Hetero receives generic Sofosbuvir+Velpatasvir approval for India
  • India, Hyderabad, 5th May, 2017: Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs, announced today that it has received the approval for the generic version of ’Sofosbuvir+Velpatasvir’ combination from Drugs Controller General of India. Read more
  • 02 Jul 2016
  • Hetero launches Biosimilar Bevacizumab
  • Hetero, one of India's leading generic pharmaceutical companies, today announces the launch of Biosimilar 'Bevacizumab' in India for the treatment of metastatic colorectal cancer (mCRC) under the brand name 'CizumabTM' Read more
  • 16 Dec 2015
  • Correct trademark name of Ledipasvir-Sofosbuvir is 'Ledifos'
  • This is with reference to the press release dated 9th December 2015 on the DCGI approval for Ledipasvir-Sofosbuvir. Hetero would like to clarify that there was an error in the brand name of the fixed-dose combination drug 'Ledipasvir-Sofosbuvir'. It was published as Ledisof. Read more
  • 03 Aug 2015
  • Hetero announces the launch of Biosimilar Rituximab (MABALL) in India
  • India, Hyderabad, 3rd August 2015: Hetero group, one of India's leading generic pharmaceutical companies and one of the world's largest global producer of anti-retroviral drugs for HIV/AIDS treatment, today announces the successful launch of its biosimilar? Rituximab? under the brand name MABALL in India. Read more
NEXT